Literature DB >> 8384422

Intracellular mechanisms mediating reversal of beta-adrenergic stimulation in intact beating hearts.

L Talosi1, I Edes, E G Kranias.   

Abstract

The changes in 32P labeling of phosphoproteins were studied in Langendorff-perfused guinea pig hearts during reversal of the stimulatory effects of isoproterenol. Exposure of the hearts to isoproterenol was associated with significant increases in adenosine 3',5'-cyclic monophosphate (cAMP) levels and in the phosphate incorporation into phospholamban in sarcoplasmic reticulum, the 15-kDa protein in the sarcolemma, and troponin I in the myofibrils. Phospholamban was phosphorylated on serine and threonine residues, both of which are sites for cAMP-dependent and Ca(2+)-calmodulin-dependent protein kinases, respectively. Termination of isoproterenol infusion was associated with reversal of the mechanical effects of isoproterenol stimulation and reversal of the increases in tissue cAMP levels. However, the decreases in cAMP levels correlated only with dephosphorylation of phosphoserine in phospholamban. Dephosphorylation of phosphothreonine in phospholamban, the 15-kDa sarcolemmal protein, and troponin I occurred at a slower rate. These findings suggest that cAMP-dependent phosphorylation of phospholamban (phosphoserine) may play a prominent role during beta-adrenergic stimulation of intact hearts.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384422     DOI: 10.1152/ajpheart.1993.264.3.H791

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  11 in total

1.  Myofilament-based relaxant effect of isoprenaline revealed during work-loop contractions in rat cardiac trabeculae.

Authors:  Joanne Layland; Jonathan C Kentish
Journal:  J Physiol       Date:  2002-10-01       Impact factor: 5.182

2.  AFos inhibits phenylephrine-mediated contractile dysfunction by altering phospholamban phosphorylation.

Authors:  Mark Y Jeong; John S Walker; R Dale Brown; Russell L Moore; Charles S Vinson; Wilson S Colucci; Carlin S Long
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-02       Impact factor: 4.733

3.  Beta 2-adrenoceptor activation by zinterol causes protein phosphorylation, contractile effects and relaxant effects through a cAMP pathway in human atrium.

Authors:  A J Kaumann; L Sanders; J A Lynham; S Bartel; M Kuschel; P Karczewski; E G Krause
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

Review 4.  Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome.

Authors:  Evangelia G Kranias; Roger J Hajjar
Journal:  Circ Res       Date:  2012-06-08       Impact factor: 17.367

Review 5.  Beta-adrenergic receptor signaling in the heart: role of CaMKII.

Authors:  Michael Grimm; Joan Heller Brown
Journal:  J Mol Cell Cardiol       Date:  2009-10-31       Impact factor: 5.000

6.  Characterization of the molecular form of cardiac phospholamban.

Authors:  J M Harrer; E G Kranias
Journal:  Mol Cell Biochem       Date:  1994-11-23       Impact factor: 3.396

Review 7.  Electrophysiological remodeling in heart failure.

Authors:  Yanggan Wang; Joseph A Hill
Journal:  J Mol Cell Cardiol       Date:  2010-01-20       Impact factor: 5.000

Review 8.  Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization.

Authors:  P V Sulakhe; X T Vo
Journal:  Mol Cell Biochem       Date:  1995 Aug-Sep       Impact factor: 3.396

Review 9.  SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope.

Authors:  Markus B Sikkel; Carl Hayward; Kenneth T MacLeod; Sian E Harding; Alexander R Lyon
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

10.  Molecular noise filtering in the β-adrenergic signaling network by phospholamban pentamers.

Authors:  Daniel Koch; Alexander Alexandrovich; Florian Funk; Ay Lin Kho; Joachim P Schmitt; Mathias Gautel
Journal:  Cell Rep       Date:  2021-07-27       Impact factor: 9.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.